<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00037128</url>
  </required_header>
  <id_info>
    <org_study_id>GL97-01</org_study_id>
    <nct_id>NCT00037128</nct_id>
  </id_info>
  <brief_title>Study of GL701 in Men With Systemic Lupus Erythematosus</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genelabs Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genelabs Technologies</source>
  <brief_summary>
    <textblock>
      Lupus flares and other symptoms associated with systemic lupus erythematosus (SLE) may be&#xD;
      caused by a deficiency of dehydroepiandrosterone (DHEA). GL701 is an investigational new drug&#xD;
      meant to enhance DHEA levels. This study is designed to evaluate both the safety and efficacy&#xD;
      of GL701 in male lupus patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 1998</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>40</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GL701</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Patient must have a diagnosis of SLE &gt; 6 months according to the 1989 revised ACR&#xD;
             criteria. Patient must meet at least four of the eleven ACR criteria for systemic&#xD;
             lupus&#xD;
&#xD;
          -  Patient must have a modified SLEDAI score &gt; 3 at both screening and qualifying visits&#xD;
             (Appendix A-2)&#xD;
&#xD;
          -  Patient must be treated for SLE with doses of prednisone &lt; 30 mg/day (including those&#xD;
             on NO glucocorticoid therapy) unchanged for &gt; 6 weeks prior to study entry (including&#xD;
             both screening and qualifying visits). Prednisone dose in patient's receiving&#xD;
             alternate day therapy will be the mean daily prednisone dose&#xD;
&#xD;
          -  Patient treated with azathioprine, methotrexate, or hydrochloroquine must be on a&#xD;
             stable dose with no change in dose for at least 6 weeks preceding the study&#xD;
&#xD;
          -  Patient must be able to read and speak English and willing to sign an informed consent&#xD;
             in English&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Patient with a history of prostate cancer&#xD;
&#xD;
          -  Patient with elevated Prostate Specific Antigen (PSA)&#xD;
&#xD;
          -  Patient diagnosed with liver disease, defined as AST or ALT &gt; 3x the upper limit of&#xD;
             normal&#xD;
&#xD;
          -  Patient ingesting body building/anabolic steroids within the last 6 months preceding&#xD;
             the study&#xD;
&#xD;
          -  Patient with end stage renal disease or receiving hemodialysis treatment&#xD;
&#xD;
          -  Patient with serum creatinine &gt; 2 mg/dl or creatinine clearance &lt; 60 ml/min&#xD;
&#xD;
          -  Patient receiving treatment with ACTH within the 3 months preceding study entry&#xD;
&#xD;
          -  Patient receiving androgens, immunoglobulins, cyclophosphamide, cyclosporin A, or&#xD;
             other immunosuppressive agents, except azathioprine, methotrexate, and&#xD;
             hydrochloroquine within the last 3 months&#xD;
&#xD;
          -  Patient with known hypersensitivity to DHEA or the inactive ingredients used in the&#xD;
             GL70l formulation (cornstarch, lactose, and magnesium stearate)&#xD;
&#xD;
          -  Patient who participated in any prior DHEA study or administration of DHEA within the&#xD;
             past 3 months&#xD;
&#xD;
          -  Patient using any investigational agents within the longer of 30 days or 10 half-lives&#xD;
             of the agent&#xD;
&#xD;
          -  Patient with any condition which in the Investigator's or sponsor's opinion is&#xD;
             sufficient to prevent adequate compliance with the study or likely to confuse&#xD;
             follow-up evaluation (e.g.. alcoholism, drug addiction, acute withdrawal from chemical&#xD;
             dependency, psychiatric disease)&#xD;
&#xD;
          -  Patient requires treatment/medication prohibited by protocol&#xD;
&#xD;
          -  Patient with any serious EKG abnormality as determined by the Investigator&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Genelabs Technologies, Inc.</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2004</verification_date>
  <study_first_submitted>May 16, 2002</study_first_submitted>
  <study_first_submitted_qc>May 16, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2002</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Lupus</keyword>
  <keyword>SLE</keyword>
  <keyword>DHEA</keyword>
  <keyword>GL701</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

